New fully compliant and validated system optimises all clinical label development processes to deliver a seamless process for sponsors
Almac Clinical Services, part of the Almac Group, has released its enhanced Label Approval Solution (LAS). The new offering is a fully compliant and validated system providing sponsors with an end-to-end solution to manage their clinical labels more effectively from Protocol to Print.
LAS is built on Almac's customer experience initiative and the company's an ongoing focus to provide customers with flexible, innovative and efficient processes.
"We understand our customer’s challenges and we have the resources, experience and expertise to manage the range of labelling scenarios they may face. Our enhanced Label Approval Solution provides sponsors with an end-to-end review process that ensures labels meet the needs of clinical sites and patients," explained Nathan Kohner, Almac Clinical Services’ Label Service Solutions Manager.
Kohner continued: "By designing labels based on clinical knowledge, unique and compliant design strategies can be developed to deliver sponsor-specific solutions that suit the needs of and individual while mitigating risks, optimising workflow processes, saving time and money and safeguarding the patient. I am delighted to launch this solution that further cements our commitment to the advancement of human health.”
Our enhanced Label Approval Solution provides sponsors with an end-to-end review process that ensures labels meet the needs of clinical sites and patients
The new service will enable sponsors to have access to the latest online technology thereby streamlining review, mark up and approval of label proofs, master text production and label text localisation.
Almac's LAS optimises all clinical label development processes, with dedicated project management teams and supporting centralised technology to deliver a seamless process for sponsors.
In an era of change and digitalisation, labels are one clinical supply item that often defines the critical path in the supply chain. These emerging technologies are reshaping the clinical trial landscape and with this brings a wealth of opportunities to use technology to increase R&D productivity and provide the information that sponsors need to optimise decision-making.